A consortium of leading global investors including Temasek and Sequoia Capital China has joined the $90-million Series A financing round of Shanghai-based biotech startup JW Therapeutics, according to an official announcement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
